Leica Microsystems releases fully automated HER2 FISH test

Breast Cancer Specimen stained with the Leica HER2 FISH System showing amplification of the HER2 gene

Leica Microsystems has announced the European release of the fully automated Leica HER2 FISH System for the Leica BOND advanced staining system.

Breast Cancer Specimen stained with the Leica HER2 FISH System showing amplification of the HER2 gene

Designed for easy and accurate assessment of HER2 gene status in breast cancer tissue, the Leica HER2 FISH System combines the use of the gold standard PathVysion®* HER2 FISH probes, supplied by Abbott Molecular Inc, with Leica’s industry-leading BOND automated platform, delivering accurate results for diagnostic confidence.

Automation of labor intensive FISH techniques reduces process variation while offering walk-away convenience. Samples can be processed continuously, eliminating the need to batch cases, offering fast turnaround times, saving valuable hands-on time and allowing rapid reporting of patient results. This fully automated system uses an optimized ready-to-use Leica HER2 FISH reagent kit with a robust BOND protocol to produce consistent, high quality stained slides. The system enhances the laboratory workflow, increasing efficiency and enabling the laboratory to provide a responsive service to their clinicians and clients.

Arnd Kaldowski, President of Leica Biosystems, commented: “Our HER2 FISH test provides improved workflow for the laboratory while maintaining the highest standard associated with HER2 FISH testing. Leica BOND users are now able to perform a full compliment of IHC and ISH breast testing on our BOND system, offered through our Theranostics and Novocastra™ product lines, delivering the diagnostic confidence needed for effective patient management.”

*PathVysion® is a trademark of Abbott Molecular Inc. All Rights Reserved. Used under License.

**Herceptin® is a trademark of Genentech, Inc. and F. Hoffmann-La Roche Ltd.